• HOME
  • ABOUT IASO
    • Company Overview
    • Management Team
    • Scientific Advisory Board
    • Partnership
  • SCIENCE & PRODUCTS
    • Pipeline
    • Technology Platforms
    • Manufacturing
    • Publictaions
    • Expanded Access
  • NEWS
    • Press Release
    • Media Report
  • CAREERS
    • Working at IASO
    • Opportunities
  • CONTACT
    • 中文简体
    • 中文繁体
    • English

Focusing on innovative
biotherapies to bring
hope of cure to patients

We aspire to bring new and curative 

treatment in the fields of hematologic  

malignancies and autoimmune

diseases

Integrated capabilities cross discovery and development to manufacturing and commercialization.

  • Pipeline

    Diversified and balanced pipeline developed with a forward-looking, de-risked development approach.

  • Technology platform

    Our leading and intergrated platforms leverage advanced technologies that span the entire product lifecycle.

  • Manufacturing

    A mature and stable CMC platform enabling large-scale, high-quality manufacturing.

News

08/122025

IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH

27/112025

IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma

20/112025

GC Cell introduces multiple myeloma CAR-T therapy from China's IASO Biotech

More
  • ABOUT IASO

    Company OverviewManagement TeamScientific Advisory BoardPartnership
  • SCIENCE & PRODUCTS

    PipelineTechnology PlatformsManufacturingPublictaionsExpanded Access
  • NEWS

    Press ReleaseMedia Report
  • CAREERS

    Working at IASOOpportunities
  • CONTACT

WeChat
LinkedIn
i-connection
Copyright © 2023 南京驯鹿生物技术股份有限公司     苏ICP备2021047135号     Privacy Policy | Terms of Use